Abbott Laboratories Investing Activities - Other 2010-2025 | ABT
Abbott Laboratories annual/quarterly investing activities - other history and growth rate from 2010 to 2025. Investing activities - other can be defined as the net amount of items a company reports that are too small to report separately. Additionally, this field holds the sum of items a company reports that cannot be assigned to any other standardized field in the investing activities section of the Cash Flows Statement
- Abbott Laboratories investing activities - other for the quarter ending March 31, 2025 was $6M, a 500% increase year-over-year.
- Abbott Laboratories investing activities - other for the twelve months ending March 31, 2025 was $23M, a 52.08% decline year-over-year.
- Abbott Laboratories annual investing activities - other for 2024 was $0.009B, a 59.09% decline from 2023.
- Abbott Laboratories annual investing activities - other for 2023 was $0.022B, a 0% decline from 2022.
- Abbott Laboratories annual investing activities - other for 2022 was $0.022B, a 15.38% decline from 2021.
| Abbott Laboratories Annual Investing Activities - Other (Millions of US $) |
|
|---|---|
| 2024 | $9 |
| 2023 | $22 |
| 2022 | $22 |
| 2021 | $26 |
| 2020 | $19 |
| 2019 | $27 |
| 2018 | $102 |
| 2017 | $2,739 |
| 2016 | $42 |
| 2015 | $52 |
| 2014 | $70 |
| 2013 | $21 |
| 2012 | $3 |
| 2011 | $1,886 |
| 2010 | $-1,888 |
| 2009 | $-6 |
| Sector | Industry | Market Cap | Revenue |
|---|---|---|---|
| Medical | Medical Products Manufacturing | $235.835B | $41.950B |
| Abbott Labs discovers, develops, manufactures & sells a diversified line of health care products. Established Pharmaceuticals Division includes branded generics business in the emerging markets. Medical Devices unit includes the diabetes care, vision care & vascular businesses. Diagnostics unit manufactures and markets diagnostic systems and tests in four business lines core laboratory, molecular, point of care and rapid diagnostics. Nutrition unit includes a broad line of pediatric and adult nutritional products. Abbott acquired CFR Pharmaceuticals, Tendyne Holdings, Inc., St. Jude Medical and Alere Inc. On the other hand, Abbott sold its developed markets branded generics pharmaceuticals business to Mylan. Abbott retained the branded generics pharmaceuticals business in emerging markets. Abbott sold its animal health business to Zoetis Inc and divested its vision care business, Medical Optics, to Johnson & Johnson. | |||
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Boston Scientific (BSX) | United States | $157.798B | 39.50 |
| Stryker (SYK) | United States | $150.649B | 31.50 |
| EssilorLuxottica (ESLOY) | France | $134.205B | 0.00 |
| Medtronic (MDT) | Ireland | $111.543B | 16.29 |
| Lonza Group Ag (LZAGY) | Switzerland | $49.908B | 0.00 |
| Haleon (HLN) | United Kingdom | $49.033B | 27.90 |
| ResMed (RMD) | United States | $37.148B | 27.90 |
| GE HealthCare Technologies (GEHC) | United States | $33.471B | 15.89 |
| Agilent Technologies (A) | United States | $32.342B | 21.36 |
| Terumo (TRUMY) | Japan | $27.583B | 35.83 |
| Insulet (PODD) | United States | $22.931B | 90.01 |
| Koninklijke Philips (PHG) | Netherlands | $22.436B | 16.13 |
| Zimmer Biomet Holdings (ZBH) | United States | $18.948B | 12.17 |
| Baxter (BAX) | United States | $16.150B | 12.06 |
| Smith & Nephew SNATS (SNN) | United Kingdom | $12.745B | 0.00 |
| Sunny Optical Technology (SNPTF) | China | $9.032B | 0.00 |
| Demant (WILYY) | Denmark | $8.231B | 0.00 |
| Bio-Rad Laboratories (BIO) | United States | $6.767B | 23.55 |
| Lantheus Holdings (LNTH) | United States | $5.414B | 13.66 |
| Prestige Consumer Healthcare (PBH) | United States | $4.395B | 19.63 |
| Perrigo (PRGO) | Ireland | $3.739B | 9.48 |
| Haemonetics (HAE) | United States | $3.484B | 15.18 |
| Shandong Weigao Medical Polymer (SHWGF) | China | $3.459B | 0.00 |
| ICU Medical (ICUI) | United States | $3.396B | 25.05 |
| Envista Holdings (NVST) | United States | $3.000B | 24.93 |
| QuidelOrtho (QDEL) | United States | $2.203B | 15.15 |
| GN Store Nord (GNNDY) | Denmark | $2.097B | 17.37 |
| LeMaitre Vascular (LMAT) | United States | $1.942B | 43.41 |
| AtriCure (ATRC) | United States | $1.604B | 0.00 |
| Neogen (NEOG) | United States | $1.389B | 17.78 |
| Kestra Medical Technologies (KMTS) | United States | $1.245B | 0.00 |
| AdaptHealth (AHCO) | United States | $1.213B | 12.31 |
| Green Thumb Industries (GTBIF) | United States | $1.175B | 26.43 |
| BioLife Solutions (BLFS) | United States | $1.090B | 0.00 |
| InMode (INMD) | Israel | $1.011B | 9.25 |
| Phibro Animal Health (PAHC) | United States | $0.978B | 12.50 |
| CeriBell (CBLL) | United States | $0.644B | 0.00 |
| Evolus (EOLS) | United States | $0.638B | 0.00 |
| Curaleaf Holdings (CURLF) | Canada | $0.566B | 0.00 |
| Maravai LifeSciences Holdings (MRVI) | United States | $0.553B | 0.00 |
| Owens & Minor (OMI) | United States | $0.548B | 4.54 |
| Valneva SE (VALN) | France | $0.530B | 0.00 |
| Capricor Therapeutics (CAPR) | United States | $0.474B | 0.00 |
| Tilray Brands (TLRY) | Canada | $0.456B | 0.00 |
| Surmodics (SRDX) | United States | $0.422B | 0.00 |
| Cresco Labs (CRLBF) | United States | $0.349B | 0.00 |
| SNDL (SNDL) | Canada | $0.342B | 0.00 |
| VAREX IMAGING (VREX) | United States | $0.330B | 12.14 |
| Canopy Growth (CGC) | Canada | $0.302B | 0.00 |
| SEMPERIT AG HLD (SEIGY) | Austria | $0.300B | 0.00 |
| Aurora Cannabis (ACB) | Canada | $0.282B | 50.20 |
| Sanara MedTech (SMTI) | United States | $0.277B | 0.00 |
| Viemed Healthcare (VMD) | United States | $0.267B | 22.50 |
| Sanuwave Health (SNWV) | United States | $0.253B | 0.00 |
| Cerus (CERS) | United States | $0.252B | 0.00 |
| Verano Holdings (VRNOF) | United States | $0.250B | 0.00 |
| ZimVie (ZIMV) | United States | $0.244B | 11.08 |
| Biote (BTMD) | United States | $0.222B | 6.25 |
| Brainsway (BWAY) | Israel | $0.201B | 53.25 |
| OraSure Technologies (OSUR) | United States | $0.197B | 0.00 |
| Omeros (OMER) | United States | $0.195B | 0.00 |
| High Tide (HITI) | Canada | $0.190B | 0.00 |
| Quanterix (QTRX) | United States | $0.189B | 0.00 |
| Utah Medical Products (UTMD) | United States | $0.177B | 14.41 |
| Organigram Global (OGI) | Canada | $0.175B | 0.00 |
| TriSalus Life Sciences (TLSI) | United States | $0.167B | 0.00 |
| Exagen (XGN) | United States | $0.135B | 0.00 |
| FitLife Brands (FTLF) | United States | $0.130B | 15.94 |
| Jin Medical (ZJYL) | China | $0.126B | 0.00 |
| TerrAscend (TSNDF) | Canada | $0.116B | 0.00 |
| Agape ATP (ATPC) | $0.102B | 0.00 | |
| MacroGenics (MGNX) | United States | $0.100B | 0.00 |
| Oramed Pharmaceuticals (ORMP) | United States | $0.087B | 0.00 |
| Fonar (FONR) | United States | $0.084B | 10.81 |
| Veru (VERU) | United States | $0.076B | 0.00 |
| Jushi Holdings (JUSHF) | United States | $0.073B | 0.00 |
| InterCure (INCR) | Israel | $0.072B | 0.00 |
| Zynex (ZYXI) | United States | $0.071B | 0.00 |
| Quipt Home Medical (QIPT) | United States | $0.060B | 0.00 |
| United Health Products (UEEC) | United States | $0.058B | 0.00 |
| Apyx Medical (APYX) | United States | $0.056B | 0.00 |
| Cytosorbents (CTSO) | United States | $0.053B | 0.00 |
| ImmuCell (ICCC) | United States | $0.050B | 0.00 |
| Modular Medical (MODD) | United States | $0.040B | 0.00 |
| United-Guardian (UG) | United States | $0.040B | 13.69 |
| Rockwell Medical (RMTI) | United States | $0.036B | 0.00 |
| Safety Shot (SHOT) | United States | $0.030B | 0.00 |
| Allurion Technologies (ALUR) | United States | $0.023B | 0.00 |
| Nephros (NEPH) | United States | $0.023B | 30.71 |
| INLIF (INLF) | $0.018B | 0.00 | |
| Flora Growth (FLGC) | United States | $0.015B | 0.00 |
| Trinity Biotech (TRIB) | Ireland | $0.015B | 0.00 |
| Cellectar Biosciences (CLRB) | United States | $0.012B | 0.00 |
| Meihua Medical Technologies (MHUA) | China | $0.009B | 0.00 |
| Innovative Eyewear (LUCY) | United States | $0.008B | 0.00 |
| Senestech (SNES) | United States | $0.005B | 0.00 |
| GlucoTrack (GCTK) | United States | $0.004B | 0.00 |
| IM Cannabis (IMCC) | Canada | $0.003B | 0.00 |
| Akanda (AKAN) | Canada | $0.002B | 0.00 |
| Sharps Technology (STSS) | United States | $0.000B | 0.00 |
| InVivo Therapeutics Holdings (NVIVQ) | United States | $0.000B | 0.00 |
| Acuren (TIC) | United States | $0.000B | 0.00 |